10.03.2023 • News

Solenis Takes Diversey for $4.6 Billion

US specialty chemicals company Solenis is to take over disinfectant producer Diversey Holdings in an all-cash transaction valued at about $4.6 billion, including debt.

“The merger presents a unique opportunity to enhance value and create a more diversified business with increased scale, broader global reach, and superior customer service capabilities,” said Diversey CEO Phil Wieland. “It will enable the combined company to grow and provide a number of attractive cross-selling opportunities, including meeting increasing customer demand for water management, cleaning and hygiene solutions.”

Once the acquisition closes — anticipated in the second half of 2023 — Diversey will return to being a privately held company. Bain Capital took Diversey public in March 2021, having paid about $3.2 billion for a 73% stake in the Fort Mill, South Carolina-based company in September 2017.

Bain has agreed to vote in favor of the merger and will contribute about 56% of its equity into Solenis and sell the remainder to the company for cash. Diversey’s board of directors has also unanimously approved the deal.

In January 2021, Diversey became Solenis’ distribution partner for its portfolio of water and process treatment chemicals to the food and beverage industry. 

Last month, Solenis closed its purchases of Peru’s Grand Invest and the paper process chemicals business of Kolb Distribution. Solenis has been owned by private equity firm Platinum Equity since November 2021.

Author: Elaine Burridge, Freelance Journalist

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.